Skip to Content

Cognitive Disorders More Common in People Admitted for COVID-19

WEDNESDAY, Nov. 4, 2020 -- Alzheimer disease and dementia are risk factors for hospital admission due to COVID-19, according to a study published online Oct. 24 in Brain, Behavior, and Immunity.

Jingqi Zhou, Ph.D., from the University of Georgia in Athens, and colleagues examined the association of COVID-19 with 974 medical conditions and 30 blood biomarkers using data from 1,091 participants in the U.K. Biobank who tested positive for COVID-19.

The researchers found that the most significant risk factors for COVID-19 include Alzheimer disease (odds ratio, 2.29), dementia (odds ratio, 2.16), and the overall category of delirium, dementia, and amnestic and other cognitive disorders (odds ratio, 1.90). There were associations seen between genetic variants in severe acute respiratory syndrome coronavirus 2 infection-related genes and COVID-19 (odds ratio, 1.33) and other phenotypes, including immune deficiency and prostate cancer.

"Our unbiased phenome-wide study in [the] U.K. Biobank confirmed known and identified novel risk factors for COVID-19, including dementia, Alzheimer's disease, type 2 diabetes, blood biomarkers of cardiovascular health, and genetic variants in TMPRSS2," the authors write.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load

FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...

Total Pediatric ED Visits Decreased in 2020 Versus 2018, 2019

FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...

Tocilizumab Does Not Improve Outcomes in Severe COVID-19

THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.